- Home
- PNW vs QGEN Comparison
PNW vs QGEN Comparison
Compare PNW & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNW | QGEN |
|---|---|---|
| Founded | 1985 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | PNW | QGEN |
|---|---|---|
| Price | $88.80 | $45.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $95.73 | $50.07 |
| AVG Volume (30 Days) | 1.1M | ★ 1.1M |
| Earning Date | 11-03-2025 | 02-04-2026 |
| Dividend Yield | ★ 4.12% | 3.33% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | ★ 4.92 | 1.84 |
| Revenue | ★ $5,307,180,000.00 | $2,070,781,000.00 |
| Revenue This Year | $4.96 | $7.07 |
| Revenue Next Year | $4.02 | $6.14 |
| P/E Ratio | ★ $17.98 | $24.67 |
| Revenue Growth | ★ 5.70 | 5.32 |
| 52 Week Low | $81.47 | $37.63 |
| 52 Week High | $96.50 | $51.88 |
Technical Indicators
Market Signals| Indicator | PNW | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 48.33 |
| Support Level | $86.82 | $45.13 |
| Resistance Level | $89.25 | $46.17 |
| Average True Range (ATR) | 1.11 | 0.63 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 81.88 | 66.17 |
Price Performance
Historical ComparisonAbout PNW Pinnacle West Capital Corporation
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).